Freedom Biosciences is a biotechnology platform developing next-generation neuropsychiatric therapeutics based on ketamine pharmacology. The company focuses on creating novel antidepressants with improved efficacy and safety profiles for debilitating mental health disorders. Their pipeline includes clinical and preclinical programs targeting treatment-resistant depression and comorbid substance use disorders.
Funding
$12M raised to dateRaised to date based on public sources. This may differ from the amount the company actually raised and is based only on what is publicly available on the internet.
Founders
Product
Problem
Existing treatments for mental health conditions like treatment-resistant depression and substance use disorders often have limited efficacy or undesirable side effects. There is a need for new therapeutic options that can improve patient outcomes and address the underlying neurobiological mechanisms of these disorders.
Solution
Freedom Biosciences is developing next-generation neuropsychiatric therapeutics by creating combination therapies using ketamine and other neuropsychiatric agents. Their discovery platform identifies optimal chemical combinations to enhance the safety and efficacy profiles of existing therapeutics. By leveraging the known pharmacology of ketamine, 5-HT2A receptors, and other novel targets, Freedom Biosciences aims to create more effective treatments for debilitating mental health disorders. The company has a pipeline of clinical and preclinical programs targeting treatment-resistant depression and comorbid major depressive disorder with substance use disorder.
Target Audience
The primary target audience includes individuals suffering from treatment-resistant depression, comorbid major depressive disorder and substance use disorder, and the clinicians who treat them.
Features
- Combination therapies utilizing ketamine and other neuropsychiatric agents
- Discovery platform to identify optimal chemical combinations
- Focus on enhancing safety and efficacy of existing therapeutics
- Pipeline programs targeting treatment-resistant depression
- Pipeline programs targeting comorbid major depressive disorder and substance use disorder